What are we comparing?
When we talk about “blockers” in adolescent gender affirming care, we are often talking about two very different categories of medication as if they are interchangeable. They are not.
At QueerDoc we commonly use:
- GnRH agonists (puberty blockers like leuprolide)
- Anti-androgens such as bicalutamide
Both are used to support transgender and gender diverse youth who have bodies that produce testosterone. Both can reduce the impact of testosterone on the body. But they do this in very different ways, and those differences matter when we are thinking about goals, safety, and long-term development. We’ll be writing a future blog about options for youth with bodies that primarily produce estrogen.
Before we go further, we need to be very clear about something that often gets glossed over:
Both of these medications are used off-label for gender dysphoria.
GnRH agonists are FDA-approved for conditions like precocious puberty and prostate cancer, but not specifically for gender affirming care. However, they have been used in transgender medicine for decades and are supported by major medical organizations. We have more data, more clinical experience, and more consensus around their use in adolescents compared to bicalutamide.
Bicalutamide is also used off-label. It was developed for prostate cancer and has far less data in transgender populations, particularly in adolescents. The data we do have is emerging and is based on smaller studies, clinical experience, and extrapolation from other populations.
So while both are off-label, they are not equal in terms of how much evidence is available to us.
What is a puberty blocker?
Puberty blockers (GnRH agonists) work in the brain. They suppress the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Without these signals, the testes do not produce testosterone.
The result is a pause in puberty.
This means that testosterone-driven secondary sex characteristics do not continue to develop. Voice deepening, facial hair growth, and other changes are halted at whatever stage treatment begins. Puberty blockers do not feminize or masculinize the body. They simply stop the progression of endogenous puberty.
Because testosterone production is suppressed, there is also a reduction in testosterone-driven genital function over time. For some patients this aligns with their goals. For others, this is an important consideration when choosing a treatment approach.
What is bicalutamide?
Bicalutamide works in a completely different way. It does not suppress testosterone production. Instead, it blocks androgen receptors in the body, preventing testosterone and dihydrotestosterone from exerting their effects.
Testosterone levels in the blood stream often remain the same or increase when someone is taking bicalutamide. However, because the receptors are blocked, the body cannot use that testosterone effectively in many tissues.
Some of that unused testosterone is converted into estrogen inside the body through aromatization. This is why bicalutamide may lead to some feminizing effects, including breast development, even without the addition of exogenous estrogen.
Because testosterone remains present in the body, there is often more preservation of testosterone-driven genital function compared to puberty blockers. This can be an important factor for patients whose goals include maintaining that function.
So while puberty blockers pause puberty, bicalutamide changes how puberty is experienced.
Are these medications interchangeable?
No.
Puberty blockers suppress the production of testosterone. Bicalutamide blocks the action of testosterone at the cellular level. Because of this, puberty blockers are much more effective at fully stopping testosterone-driven pubertal progression.
Bicalutamide does not completely halt puberty. Some androgen effects may still occur, particularly in tissues where bicalutamide does not fully block testosterone receptors.
This difference also shows up in how the body functions day-to-day. With puberty blockers, lower testosterone levels often mean reduced genital function. With bicalutamide, because testosterone is still present, that function may be better preserved.
For adolescents early in puberty who want to prevent further masculinization, GnRH agonists are generally the more effective option when they are accessible.
Why would we choose one over the other?
Access (money! 💲💰💸 paperwork! 📝 insurance! 🔐) is a big part of this conversation, but it is not the only part.
We think about:
Stage of puberty
If someone is very early in puberty and the goal is to prevent any further testosterone-driven development, puberty blockers are usually the most effective option.
If someone is later in puberty, some changes have already occurred, and the goal may shift toward reducing ongoing masculinization and possibly supporting feminization. In that context, bicalutamide may be part of the conversation.
Patient goals
Some patients want a full pause. Others want to actively move toward feminization. Puberty blockers and bicalutamide support different goals, and those goals matter.
Genital function is one of those goals. Some patients want to reduce or eliminate testosterone-driven genital function. Others want to maintain it. Because puberty blockers suppress testosterone production, they are more likely to reduce this function. Bicalutamide, by allowing testosterone to remain in circulation, may better preserve it.
Again, this is not about better or worse. It is about alignment with what the patient wants for their body.
Underlying health conditions
Certain medical conditions may make one option safer or more appropriate than the other. For example, concerns about liver health may limit the use of bicalutamide, while other factors may influence whether GnRH agonists are a good fit.
Ability to monitor and follow up
Both medications require monitoring, but the type and urgency of labs and monitoring tests differ. Bicalutamide requires careful attention to liver health. Puberty blockers require ongoing assessment of bone health and development.
Access and cost
Puberty blockers are expensive and often difficult to access. Bicalutamide is significantly more accessible for many patients. But access is one factor among many, not the only reason we make this decision.
What about safety?
Puberty blockers have been used for decades in pediatric populations, particularly for the treatment of precocious puberty. Their safety profile is relatively well understood, with the primary concerns being cost, access, and effects on bone density.
Bicalutamide has a different risk profile. It has been associated with rare but serious liver injury, including cases of death. Much of this data comes from older cisgender men treated for prostate cancer. Data in transgender adolescents is limited and still emerging.
At QueerDoc we take this risk seriously. We use the lowest effective doses, monitor liver function, and provide clear education on symptoms that require immediate evaluation. Informed consent is central to this process.
Final thoughts
Adolescent gender affirming care requires balancing physiology, patient goals, safety, and real-world access. Puberty blockers and bicalutamide are not equivalent, and they are not interchangeable, but both can play a role depending on the situation.
At QueerDoc we focus on individualized, consent-driven care that acknowledges both the medical evidence and the realities our patients face.
There is no one way to be trans. There is no one way to approach gender affirming care. But there are ways to do it thoughtfully, transparently, and in a way that actually supports the person in front of us.
